ロード中...
A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of developing metastasis and subsequent disease-rel...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Cancer Intelligence
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3234061/ https://ncbi.nlm.nih.gov/pubmed/22275984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2008.108 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|